Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.43 |
| ▸ | TCF4 | P15884 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | DHODH | Q02127 | 10/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26075893 | 0.88 | ESR1 (0.37) | APPTCF4CTNNB1KDM1AESR1 | |
| SCHEMBL26075136 | 0.88 | ESR1 (0.50) | DHODHDHFRALKBH5ESR1ESR2 | |
| SCHEMBL26074092 | 0.87 | APP (0.49) | APPTCF4CTNNB1KDM1ADHODH | |
| SCHEMBL26075419 | 0.86 | KDM1A (0.46) | APPKDM1ADHODHDHFRESR1 | |
| SCHEMBL23590280 | 0.84 | DHODH (0.59) | DHODHDHFRALKBH5ESR1ESR2 | |
| SCHEMBL26075318 | 0.83 | APP (0.43) | APPDHODHDHFRALKBH5ESR1 | |
| SCHEMBL26075230 | 0.83 | PLA2G2A (0.54) | APPDHODHMEN1KMT2A | |
| SCHEMBL26075308 | 0.82 | DHODH (0.55) | DHODHDHFRALKBH5ESR1ESR2 | |
| SCHEMBL26075137 | 0.81 | DHODH (0.51) | DHODHDHFRALKBH5ESR1ESR2 | |
| SCHEMBL26075130 | 0.81 | HMOX1 (0.43) | DHODHMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | DHODH, CD38, DPYD | APP 1602/4885TCF4 4528/4885CTNNB1 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.